CDXS Overview

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Wall Street analysts forecast CDXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDXS is6.00 USD with a low forecast of 2.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Codexis Inc revenue for the last quarter amounts to 38.91M USD, increased 81.34

Codexis Inc. EPS for the last quarter amounts to 0.11 USD, decreased -184.62

Codexis Inc (CDXS) has 146 emplpoyees as of April 01 2026.

Today CDXS has the market capitalization of 138.12M USD.